Editas Medicine, Inc. CEO and Director Gilmore O'Neill filed a Form 4 on November 6, 2026, disclosing the acquisition of 43,567 shares of common stock on November 5, 2026, through the vesting of a performance-based restricted stock unit award tied to the achievement of a specified research and development milestone.

Key Highlights

  • Shares acquired: 43,567 shares of common stock were acquired on November 5, 2026, at a price of $0.
  • Transaction type: The acquisition (code A) reflects vesting of a performance-based restricted stock unit award originally granted on March 2, 2024.
  • Milestone trigger: Vesting occurred upon the achievement of a specified research and development milestone, according to the filing.
  • Post-transaction ownership: Following the transaction, O'Neill directly holds 286,756 shares of common stock.
  • Reporting person role: Gilmore O'Neill is identified as both CEO and Director of Editas Medicine, Inc.

CEO Gilmore O'Neill Receives Milestone-Vested RSU Shares at Editas Medicine

According to the Form 4 filed with the SEC on November 6, 2026, Gilmore O'Neill, who serves as both CEO and Director of Editas Medicine, Inc. (NASDAQ:EDIT), reported the acquisition of 43,567 shares of the company's common stock. The transaction date is listed as November 5, 2026, and the shares were acquired at a price of $0, reflecting a vesting event rather than an open-market purchase.

The filing states that the acquisition "reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on March 2, 2024." The transaction was recorded under acquisition code "A" in Table I of the Form 4, covering non-derivative securities. No derivative securities transactions were reported in Table II.

Following this transaction, O'Neill's direct beneficial ownership of Editas Medicine common stock stands at 286,756 shares, as reported in the filing. The Form 4 was filed by O'Neill as a single reporting person, and the ownership is listed as direct. No indirect beneficial ownership was disclosed in connection with this transaction.

What Was Disclosed

Gilmore O'Neill, CEO and Director of Editas Medicine, disclosed the vesting of 43,567 performance-based RSU shares on November 5, 2026, triggered by an R&D milestone. His total direct beneficial ownership following the transaction is reported as 286,756 shares.